论文部分内容阅读
目的评价rhIL-11(巨和粒)在化疗所致血小板减少治疗中的作用。方法将65例化疗后血小板减少的患者随机分为对照组(33例):予常规止血及对症、支持治疗;试验组(32例):除与对照组同样治疗外,加皮下注射巨和粒1.5mg/次,1次/d,比较两组治疗后外周血血小板计数变化及出血症状改善情况。结果试验组血小板计数回升、出血症状的改善较对照组快,血小板计数回升至100×109/L以上的平均时间比对照组短,分别为(5.5±0.5)d和(9.6±1.2)d,两组差异有显著性(P<0.01)。结论巨和粒对化疗所致血小板减少疗效显著,无明显副作用。
Objective To evaluate the role of rhIL-11 in treating thrombocytopenia induced by chemotherapy. Methods Thirty-six patients with thrombocytopenia after chemotherapy were randomly divided into control group (n = 33): conventional hemostasis and symptomatic treatment, and supportive treatment. In the experimental group (32 cases), except the same treatment as the control group, 1.5mg / time, 1 time / d, comparing the changes of peripheral blood platelet count and the improvement of bleeding after treatment in both groups. Results In the experimental group, the platelet counts rose and the bleeding symptoms improved more rapidly than those in the control group. The mean time to platelet count up to 100 × 109 / L was (5.5 ± 0.5) days and (9.6 ± 1.2) days respectively, The difference between the two groups was significant (P <0.01). Conclusion Giant and tablets of chemotherapy-induced thrombocytopenia significant effect, no significant side effects.